Bliss GVS Pharma Rallies 45% in 10 Sessions Via The Anupam Rasayan Deal and Two Other Catalysts

Synopsis: A rare convergence of a Rs. 2,198 crore control-change acquisition by Anupam Rasayan India, a fresh WHO-GMP certification for its Palghar manufacturing unit, and a 129 percent jump in Q4 FY26 net profit has sent Bliss GVS Pharma surging over 45 percent across 10 trading sessions and 61 percent in a single calendar month  its best monthly performance since 2015.

Shares of a four-decade-old pharmaceutical formulation exporter have become one of the market’s most-discussed names over the past fortnight, propelled by a control-change acquisition agreement, a key regulatory clearance, and results that beat the prior year by a wide margin. The stock has gained over 45 percent in ten trading sessions, its sharpest short-term move in a decade  and sits at a 52-week high.

With a market capitalization of Rs. 4,599.18 crore, the shares of Bliss GVS Pharma Limited were trading at Rs. 434.50 per share, up 0.01 percent from its previous close. The stock is trading at a P/E of 34.11.

Catalyst 1: The Anupam Rasayan Acquisition

The primary trigger is the definitive agreement signed on May 23, 2026, under which Surat-based specialty chemicals company Anupam Rasayan India will acquire a 43.3 percent to 48.2 percent equity stake in Bliss GVS Pharma from its existing promoters at Rs. 299 per share, for a total consideration of Rs. 1,369.51 crore. 

The transaction automatically triggered SEBI’s Substantial Acquisition of Shares and Takeovers Regulations, requiring a mandatory open offer for an additional 26 percent of the paid-up capital at the same price of Rs. 299 per share, worth approximately Rs. 829 crore. If fully tendered, Anupam Rasayan’s stake could reach up to 74.2 percent, for a combined outlay of roughly Rs. 2,198.54 crore. The public tendering window is scheduled between July 16 and July 29, 2026. The deal will be funded via a Rs. 300 crore term loan, with the balance arranged through cash equivalents, bank facilities, and non-controlling, non-voting equity instruments.

The strategic logic centres on backward integration. Anupam Rasayan, a custom synthesis and specialty chemicals manufacturer, intends to supply key starting materials directly into Bliss GVS’s formulation pipeline, a move that could structurally reduce raw material costs and tighten margins.

The combined entity is positioned to accelerate entry into regulated markets in the US and Europe, where Bliss GVS already holds USFDA approval for its Palghar suppository unit and EU-GMP certification. Anupam Rasayan’s Managing Director Anand Desai described the transaction as spanning the pharmaceutical value chain from key starting materials to finished dosage formulations.

Catalyst 2: WHO-GMP Certification for the Palghar Facility

Running parallel to the acquisition news, Bliss GVS received an inspection closure report from the World Health Organization on June 2, 2026, confirming that its manufacturing facility at Survey No. 43 and 44, Vevoor Village, Palghar East, Maharashtra, now complies with WHO-GMP standards. The certification is commercially meaningful: WHO-GMP approval is a baseline requirement for tendering to United Nations procurement agencies and government health programmes across Africa and Asia  markets where Bliss GVS earns a significant portion of its revenue.

The company already holds USFDA Voluntary Action Indicated status for the Palghar unit following a 2023 inspection, and the WHO clearance now layers another regulated-market credential onto the same site.

Catalyst 3: Q4 FY26 Results

The results backdrop further supported sentiment. For the quarter ended March 2026, Bliss GVS Pharma reported consolidated revenue of Rs. 257 crore, up 29.8 percent year-on-year, while net profit rose 129 percent to Rs. 37 crore against Rs. 16 crore in Q4 FY25. The board also declared a 100 percent dividend for FY26. For the full financial year, consolidated turnover stood at Rs. 1,000.64 crore and net profit at Rs. 134.73 crore, against revenue of Rs. 810 crore and PAT of Rs. 90 crore in FY25. Net worth as of March 31, 2026 was Rs. 1,192.90 crore.

One caveat deserves mention: other income for FY26 came in at Rs. 71 crore, a large figure relative to a net profit of Rs. 135 crore, suggesting core operating earnings are more modest than the headline PAT implies. Debtor days of 204 also reflect a chronic receivables problem that has persisted through multiple years.

Business Overview

Incorporated in 1984, Bliss GVS Pharma Limited develops, manufactures, and exports pharmaceutical formulations including suppositories, pessaries, capsules, tablets, and injectables. The company is among India’s largest  and by some counts the only EU-GMP certified  suppository manufacturers, with a portfolio of over 150 branded formulations sold across 60-plus countries. Sub-Saharan Africa is its largest revenue market.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Bliss GVS Pharma Rallies 45% in 10 Sessions Via The Anupam Rasayan Deal and Two Other Catalysts appeared first on Trade Brains.